Type:10 Tablets
Generic Name:Citalopram Hydrobromide
Manufacturer:Incepta Pharmaceuticals Ltd.
Price:৳80.00
Depressive illness, Bipolar disorder, Panic disorder, Substance abuse disorders, Alcohol dependence, Anxiety disorders including obsessive-compulsive disorder and social phobia, Post-traumatic stress disorder, Premenstrual syndrome, Idiopathic Parkinson's disease and Eating disorder.
May be taken with or without food.
Oral Depression; Depressive phase of bipolar disorder Adult: Initially, 20 mg/day, increased to max 40 mg/day after at least 1 wk. Elderly: 10 mg/day. Max: 20 mg/day. Hepatic impairment: Mild to moderate: 10 mg/day for the 1st 2 wk. Max: 20 mg/day. Panic disorder with or without agoraphobia Adult: Initially, 10 mg/day, increased to 20 mg/day after 1 wk. Elderly: 10 mg/day. Max: 20 mg/day. Hepatic impairment: Mild to moderate: 10 mg/day for the 1st 2 wk. Max: 20 mg/day.
Child: Contraindicated.
Renal impairment: No dosage adjustment needed.
Hypersensitivity, concomitant admin with MAOIs or within 14 days of discontinuing MAOI treatment; children and adolescents <18 yr; treatment of depressive illness; lactation.
Citalopram is bicyclic phthalane derivative and a selective serotonin re-uptake inhibitor, w/ little or no effect on noradrenaline, dopamine and GABA re-uptake. The inhibitory activity explains the antidepressant property of citalopram. It has no or very low affinity for 5-HT1AA, 5-HT2A, D1 and D2 receptors, alpha 1, alpha2, beta-adrenergic, histamine H1, muscarinic, cholinergic, benzodiazepine and opioid receptors.
Caution should be taken in patients with epilepsy, concurrent electroconvulsive therapy, history of mania, cardiac disease, diabetes mellitus, angle-closure glaucoma, history of bleeding disorders, hepatic and renal impairment. Abrupt withdrawal of Citalopram should be avoided. Gradual discontinuation of treatment if patient enters into manic phase; pregnancy. Increased risk of hyponatraemia and SIADH. May reduce convulsant threshold thus, citalopram should be used with care in epileptic patients. Lactation: Excreted in breast milk; use caution
>10% Dry mouth (20%),Nausea (21%),Somnolence (18%),Insomnia (15%),Xerostomia (20%),Increased sweating (11%) 1-10% Tremor (8%),Diarrhea (8%),Ejaculation disorder (6%),Rhinitis (5%),Upper respiratory infection (5%),Dyspepsia (5%),Fatigue (5%),Vomiting (4%),Anxiety (4%),Anorexia (4%),Abdominal pain (3%),Agitation (3%),Impotence (3%),Sinusitis (3%),Dysmenorrhea (3%),Decreased libido (2%),Yawning (2%),Arthralgia (2%),Myalgia (2%),Amenorrhea (>1%),Confusion (>1%),Cough (>1%),Flatulence (>1%),Increased saliva (>1%),Migraine (>1%),Orthostatic hypotension (>1%),Paresthesia (>1%),Polyuria (>1%),Pruritus (>1%),Rash (>1%),Tachycardia (>1%),Weight change (>1%) Potentially Fatal: Increased risk of suicidal thinking and behaviour especially in child and adolescents. Monitor closely for signs of clinical worsening, suicidality or unusual changes in behaviour.
Pregnancy Pregnancy category: C Use late in the third trimester associated with complications in newborns and may require prolonged hospitalization, respiratory support, and tube feeding Lactation Excreted in breast milk; use caution
May increase anticoagulant effect w/ drugs affecting haemostatis (e.g. warfarin). Increased risk of hypomania w/ sibutramine. Increased lowering seizure threshold w/ TCAs and other SSRIs. Potentially Fatal: Increased risk of severe adverse effects (e.g. serotonin syndrome) w/ MAOI. QT interval prolongation w/ subsequent risk of torsade de pointes w/ QT-prolonging drugs (e.g. pimozide, quinidine, procainamide, chlorpromazine, thioridazine, amiodarone, sotalol, moxifloxacin, pentamidine, levomethadyl, methadone).
